These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 34309714)

  • 1. Outcome of COVID-19 infection in 50 multiple myeloma patients treated with novel drugs: single-center experience.
    Krejci M; Pour L; Adam Z; Sandecka V; Stork M; Sevcikova S; Krejci M; Knechtova Z; Kral Z
    Ann Hematol; 2021 Oct; 100(10):2541-2546. PubMed ID: 34309714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
    Cavo M; Gay F; Beksac M; Pantani L; Petrucci MT; Dimopoulos MA; Dozza L; van der Holt B; Zweegman S; Oliva S; van der Velden VHJ; Zamagni E; Palumbo GA; Patriarca F; Montefusco V; Galli M; Maisnar V; Gamberi B; Hansson M; Belotti A; Pour L; Ypma P; Grasso M; Croockewit A; Ballanti S; Offidani M; Vincelli ID; Zambello R; Liberati AM; Andersen NF; Broijl A; Troia R; Pascarella A; Benevolo G; Levin MD; Bos G; Ludwig H; Aquino S; Morelli AM; Wu KL; Boersma R; Hajek R; Durian M; von dem Borne PA; Caravita di Toritto T; Zander T; Driessen C; Specchia G; Waage A; Gimsing P; Mellqvist UH; van Marwijk Kooy M; Minnema M; Mandigers C; Cafro AM; Palmas A; Carvalho S; Spencer A; Boccadoro M; Sonneveld P
    Lancet Haematol; 2020 Jun; 7(6):e456-e468. PubMed ID: 32359506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis B Reactivation Rate and Fate Among Multiple Myeloma Patients Receiving Regimens Containing Lenalidomide and/or Bortezomib.
    Ataca Atilla P; Yalçıner M; Atilla E; İdilman R; Beksaç M
    Turk J Haematol; 2019 Nov; 36(4):266-273. PubMed ID: 31368290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial.
    Durie BGM; Hoering A; Abidi MH; Rajkumar SV; Epstein J; Kahanic SP; Thakuri M; Reu F; Reynolds CM; Sexton R; Orlowski RZ; Barlogie B; Dispenzieri A
    Lancet; 2017 Feb; 389(10068):519-527. PubMed ID: 28017406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
    Durie BGM; Hoering A; Sexton R; Abidi MH; Epstein J; Rajkumar SV; Dispenzieri A; Kahanic SP; Thakuri MC; Reu FJ; Reynolds CM; Orlowski RZ; Barlogie B
    Blood Cancer J; 2020 May; 10(5):53. PubMed ID: 32393732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world data on the efficacy and safety of daratumumab treatment in Hungarian relapsed/refractory multiple myeloma patients.
    Lovas S; Varga G; Farkas P; Masszi T; Wohner N; Bereczki Á; Adamkovich N; Borbényi Z; Szomor Á; Alizadeh H; Szaleczky E; Wolf K; Schneider T; Plander M; Szendrei T; Csacsovszki O; Csukly Z; Rajnics P; Egyed M; Nagy Z; Rejtő L; Illés Á; Mikala G; Váróczy L
    Int J Hematol; 2019 Nov; 110(5):559-565. PubMed ID: 31392600
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of bone-modifying agents and clinical outcomes in older adults with multiple myeloma.
    Olszewski AJ; Barth PM; Reagan JL
    Cancer Med; 2019 Nov; 8(16):6945-6954. PubMed ID: 31566898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor outcomes of immunoglobulin D multiple myeloma patients in the era of novel agents: a single-center experience.
    Zhao Q; Li F; Song P; Zhou X; An Z; Mei J; Shao J; Li H; Wang X; Guo X; Zhai Y
    Cancer Commun (Lond); 2019 Sep; 39(1):51. PubMed ID: 31558165
    [No Abstract]   [Full Text] [Related]  

  • 9. EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma.
    Tzogani K; Penninga E; Schougaard Christiansen ML; Hovgaard D; Sarac SB; Camarero Jimenez J; Garcia I; Lafuente M; Sancho-López A; Salmonson T; Gisselbrecht C; Pignatti F
    Oncologist; 2018 May; 23(5):594-602. PubMed ID: 29371479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of daratumumab, pomalidomide, and dexamethasone in patients with relapsed or refractory myeloma: Utility of re-treatment with daratumumab among refractory patients.
    Nooka AK; Joseph NS; Kaufman JL; Heffner LT; Gupta VA; Gleason C; Boise LH; Lonial S
    Cancer; 2019 Sep; 125(17):2991-3000. PubMed ID: 31090928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daratumumab Plus Bortezomib, Melphalan, and Prednisone Versus Standard of Care in Latin America for Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Propensity Score Matching Analysis.
    Hungria V; Martínez-Baños DM; Mateos MV; Dimopoulos MA; Cavo M; Heeg B; Garcia A; Lam A; Machnicki G; He J; Fernandez M
    Adv Ther; 2020 Dec; 37(12):4996-5009. PubMed ID: 33067698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disseminated Cryptococcosis in a Patient with Multiple Myeloma Treated with Daratumumab, Lenalidomide, and Dexamethasone.
    Sato S; Kambe E; Tamai Y
    Intern Med; 2019 Mar; 58(6):843-847. PubMed ID: 30449801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of the Efficacy of Thalidomide Plus Dexamethasone-Based Regimens in Patients With Relapsed/Refractory Multiple Myeloma Who Received Prior Chemotherapy, Including Bortezomib and Lenalidomide: KMM-166 Study.
    Jung KS; Kim K; Kim HJ; Kim SH; Lee JO; Kim JS; Lee JJ; Eom HS; Min CK; Shin HJ
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e97-e104. PubMed ID: 31831372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma.
    Xu XS; Dimopoulos MA; Sonneveld P; Ho PJ; Belch A; Leiba M; Capra M; Gomez D; Medvedova E; Iida S; Min CK; Schecter J; Jansson R; Zhang L; Sun YN; Clemens PL
    Adv Ther; 2018 Nov; 35(11):1859-1872. PubMed ID: 30374808
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bortezomib, lenalidomide, and dexamethasone with panobinostat for front-line treatment of patients with multiple myeloma who are eligible for transplantation: a phase 1 trial.
    Manasanch EE; Shah JJ; Lee HC; Weber DM; Thomas SK; Amini B; Feng L; Berkova Z; Hildebrandt M; Orlowski RZ
    Lancet Haematol; 2018 Dec; 5(12):e628-e640. PubMed ID: 30501870
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment Patterns and Clinical and Economic Outcomes in Patients With Newly Diagnosed Multiple Myeloma Treated With Lenalidomide- and/or Bortezomib-containing Regimens Without Stem Cell Transplant in a Real-world Setting.
    Chari A; Parikh K; Ni Q; Abouzaid S
    Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):645-655. PubMed ID: 31377207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
    Mateos MV; Sonneveld P; Hungria V; Nooka AK; Estell JA; Barreto W; Corradini P; Min CK; Medvedova E; Weisel K; Chiu C; Schecter JM; Amin H; Qin X; Ukropec J; Kobos R; Spencer A
    Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):509-518. PubMed ID: 32482541
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global Burden of Multiple Myeloma: A Systematic Analysis for the Global Burden of Disease Study 2016.
    Cowan AJ; Allen C; Barac A; Basaleem H; Bensenor I; Curado MP; Foreman K; Gupta R; Harvey J; Hosgood HD; Jakovljevic M; Khader Y; Linn S; Lad D; Mantovani L; Nong VM; Mokdad A; Naghavi M; Postma M; Roshandel G; Shackelford K; Sisay M; Nguyen CT; Tran TT; Xuan BT; Ukwaja KN; Vollset SE; Weiderpass E; Libby EN; Fitzmaurice C
    JAMA Oncol; 2018 Sep; 4(9):1221-1227. PubMed ID: 29800065
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Applicability of the International Staging System in Chinese Patients with Multiple Myeloma Receiving Bortezomib or Thalidomide-Based Regimens as Induction Therapy: A Multicenter Analysis.
    Lu J; Lu J; Liu A; Fu W; Du J; Huang X; Chen W; Hou J
    Biomed Res Int; 2015; 2015():856704. PubMed ID: 26640799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [First-line treatment of multiple myeloma].
    Breitkreutz I; Raab M; Goldschmidt H
    Internist (Berl); 2019 Jan; 60(1):23-33. PubMed ID: 30552458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.